BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
08 nov. 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
01 nov. 2018 16h10 HE
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
Abattis Bioceuticals Offers Comfort to Those Suffering with Chronic Pain & Inflammation -- CFN Media
30 oct. 2018 09h00 HE
|
CFN Media
SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of...
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29 oct. 2018 08h30 HE
|
BioDelivery Sciences International, Inc.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 ...
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
23 oct. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
25 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
13 sept. 2018 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
10 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living...
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
21 août 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
15 août 2018 09h26 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...